Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune responses to influenza and pneumococcal conjugate vaccines in older versus younger adults
2019-000836-24Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Apr 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of Prevnar 13 and influenza vaccine in pneumococcal disease and influenza, sponsored by National Institute for Public Health and the Environment. Primary endpoint: Primary: Pneumococcal serotype-specific serum IgG antibody concentrations. Started Apr 2019; status: completed.
02
Drugs
Prevnar 13influenza vaccine
03
Conditions
pneumococcal diseaseinfluenza
Beyond the preview
Go deeper on 2019-000836-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000836-24.